Discontinuation of Tyrosine Kinase Inhibitors in Chronic Myeloid Leukemia With Losing Major Molecular Response as a Definition for Molecular Relapse: A Systematic Review and Meta-Analysis

Discontinuation of Tyrosine Kinase Inhibitors in Chronic Myeloid Leukemia With Losing Major Molecular Response as a Definition for Molecular Relapse: A Systematic Review and Meta-Analysis

Background: A new goal in treatment of chronic myeloid leukemia (CML) in patients with stable deep molecular response (DMR) is maintaining durable treatment-free remission (TFR) after discontinuing tyrosine kinase inhibitor (TKI) treatment.Methods: We conducted a systematic review and meta-analysis...

Full description

Bibliographic Details
Main Authors: Kang-kang Chen, Tai-feng Du, Pei-sheng Xiong, Guan-hua Fan, Wei Yang
Format: Article
Language:English
Published: Frontiers Media S.A. 2019-05-01
Series:Frontiers in Oncology
Subjects:
tyrosine kinase inhibitors
chronic myeloid leukemia
treatment-free remission
treatment discontinuation
deep molecular response
Online Access:https://www.frontiersin.org/article/10.3389/fonc.2019.00372/full

Internet

https://www.frontiersin.org/article/10.3389/fonc.2019.00372/full

Similar Items